Undisclosed anti-PAR2 mAb / Nxera Pharma - LARVOL DELTA

Imiquimod-induced pruritus in female wild-type and knockin Wistar rats: underscoring behavioral scratching in a rat model for antipruritic treatments. (PubMed, BMC Res Notes) - "Animal models of skin disease are used to evaluate therapeutics to alleviate disease. We demonstrate that the IMQ model can be reproduced in rats, including their genetically modified derivatives, and how scratching can be used as a key behavioral endpoint. We systemically delivered an anti-PAR2 antibody (P24E1102) which reversed scratching bouts-validating this behavioral methodology and have shown its feasibility and value in identifying effective antipruritic drugs."

Journal • Preclinical • Dermatology • Immunology • Pruritus • Psoriasis

Macrophage Par2 Contributes To Influenza A Virus Pathology And Is A Potential Therapeutic Target To Treat Influenza A Virus Infection. (ATVB-PVD-GPM 2022) - "Lastly, we analyzed PAR2 inhibition in wild-type (WT) mice using mouse-anti PAR2 antibody (SAM11) and small molecule PAR2 inhibitor ENMD-1068...Global or macrophage cell but not neutrophil or lung EpC Par2 deficiency was associated with reduced IAV-induced lung pathology and mortality. Additionally, PAR2 inhibition experiments showed PAR2 may be a therapeutic target to reduce IAV pathology."

Immunology • Infectious Disease • Inflammation • Respiratory Diseases • IL6 • TLR3

Proteolytic activity of Triatoma infestans saliva associated with PAR-2 activation and vasodilation. (PubMed, J Venom Anim Toxins Incl Trop Dis) - "Anti-PAR-2 antibody completely inhibited vasodilation observed in the presence of triapsin activity. Triapsin activity also induced an increase in the mouse ear venular diameter. Data from this study suggest a plausible association between triapsin activity mediated PAR-2 activation and vasodilation caused by T. infestans saliva."

Journal

Apixaban Suppresses the Release of TF-positive Microvesicles and Restrains Cancer Cell Proliferation through Directly Inhibiting TF-fVIIa Activity (ISTH 2019) - "The cells were adapted to serum-free media before activation with fXa (10 nM) in the presence of either Apixaban (0-1 µg/ml), Rivaroxaban (0-0.6 µg/ml), an anti-fVIIa inhibitory antibody, or an anti-PAR2 inhibitory antibody. This study established that the activation of PAR2 by TF-fVIIa complex is the principal mediator in augmenting the release of TF+MV and in cancer cell proliferation. Importantly, for the first time we have shown that Apixaban selectively inhibits the proteolytic activity of fVIIa and the signalling arising from the TF-fVIIa complex."